UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Nov

    14

    New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

    Read More Share:linkedin| twitter| email

    Sep

    30

    UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

    Read More Share:linkedin| twitter| email

    Jun

    12

    UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

    Read More Share:linkedin| twitter| email

    May

    06

    Evolving Expectations for Arthritis Management

    Read More Share:linkedin| twitter| email

    Nov

    09

    Advancing Rheumatic Disease Treatment

    Read More Share:linkedin| twitter| email

    Dec

    07

    The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

    Read More Share:linkedin| twitter| email

    Nov

    17

    Shaping the Future of Psoriatic Arthritis Care in Rural Settings

    Read More Share:linkedin| twitter| email

    Nov

    10

    Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

    Read More Share:linkedin| twitter| email

    Nov

    09

    Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022

    Read More Share:linkedin| twitter| email

    Nov

    08

    UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)